Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 4:00 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (806)	2/19/2008 2:51:29 AM
From: Icebrg	of 824

Alexion Pharmaceuticals "buy," target price raised 02/18/08 - UBS NEW YORK, February 18 (newratings.com) - Analysts at UBS maintain their "buy" rating on Alexion Pharmaceuticals Inc (ALXN), while revising their estimates for the company. The target price has been raised from $82 to $86. In a research note published on February 15, the analysts mention that the company has posted robust 4Q07 results, driven by robust growth in its Soliris revenues. Alexion Pharmaceuticals’ revenue guidance might prove to be conservative, given Soliris’ robust near- and long-term growth potential, the analysts say. The R&D and SG&A expense estimates for the company have been raised to reflect its higher-then-anticipated stock option expenses and the COGS estimates have been reduced to reflect its impressive guidance, UBS adds. The EPS estimate for 2008 has been reduced from -$0.79 to -$0.85. The EPS estimate for 2009 has been raised from $1.33 to $1.39. newratings.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next